Cambridge, Mass., November 27, 2018 – Gemini Therapeutics today announced that Chief Executive Officer James McLaughlin will present a company overview at the Piper Jaffray 30th Annual Healthcare Conference in New York, NY.
The presentation will take place on Tuesday, November 27, 2018 at 8:30 a.m. ET.
Gemini Therapeutics is a product engine company using the process of redefining dry age-related macular degeneration (AMD) with precision medicine to create first-in-class therapeutics for unmet clinical needs in the eye and throughout the body. Our ocular therapeutic candidates are matched to molecular abnormalities found in patients with high clinical need and our broad multimodal pipeline includes monoclonal antibodies, recombinant proteins and gene therapies. Launched with funding from leading life science investors and powered by academic partnerships around the world, we are developing a series of first-in-class therapeutics for dry AMD and complement-mediated diseases.
For more information, visit www.GeminiTherapeutics.com.
Ten Bridge Communications